Risk of malignancy in cytologically indeterminate thyroid nodules harboring thyroid stimulating hormone receptor mutations
Dorota Whitmer(Cleveland Clinic), Joyce Shin(Cleveland Clinic), Shelby Holt(Southwestern Medical Center), Yangyang Hao(Indiana University School of Medicine), Joshua Klopper(Veracyte (United States)), John E. Phay(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Richard T. Kloos(Veracyte (United States)), Esther Wu(Veracyte (United States)), Jing Huang(Veracyte (United States)), Anthony Chi, Giulia C. Kennedy(Veracyte (United States)), Jay Nguyen, Benjamin OʼDonnell(The Ohio State University Wexner Medical Center), Dennis Joseph
Cited by 7
Related Papers
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|514
Clinical Practice Guideline: Improving Voice Outcomes after Thyroid Surgery
|Otolaryngology|2013|454
Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules
|JAMA Surgery|2018|379
Thyroid Carcinoma
|Journal of the National Comprehensive Cancer Network|2010|205
Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
|The Lancet Respiratory Medicine|2019|161